What question did this study set out to answer?

This research examines whether SGLT2 inhibitors alter the interpretation of glycemic control metrics in individuals with type 2 diabetes.

March 3, 2026

Discordance Between HbA1c and Glucose Management Indicator in People With Type 2 Diabetes Treated With SGLT2 Inhibitors

Key Points

This research examines whether SGLT2 inhibitors alter the interpretation of glycemic control metrics in individuals with type 2 diabetes.
Analyzed the impact of SGLT2 inhibitors on HbA1c and glucose management indicators (HGI)
Evaluated the role of patient-specific factors such as hematologic and renal conditions
Emphasized the importance of continuous glucose monitoring (CGM) metrics and alternative biomarkers for assessment.
SGLT2 inhibitors increase HGI levels while reducing GA/HbA1c
Alterations in glycemic markers occur independently of hematologic and renal factors
Individualized assessments of glycemic control are necessary to truly understand patient health outcomes.

Abstract

SGLT2i therapy alters the interpretation of glycemic markers by elevating HGI and lowering GA/HbA1c, independent of hematologic and renal factors. These findings emphasize the need for individualized assessment of glycemic control using CGM-derived metrics and complementary biomarkers.

Discordance Between HbA1c and Glucose Management Indicator in People With Type 2 Diabetes Treated With SGLT2 Inhibitors

Key Points

Abstract

Cite This Study